Loading
TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.
TQB3702 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in non-Hodgkin lymphoma. Described in the registry record as a tyrosine kinase inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a tyrosine kinase inhibitor; the trial entries below carry the sponsor's wording.
1.TQB3702 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB3702" OR ABSTRACT:"TQB3702") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB3702, not a curated reading list.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
Shares Non-Hodgkin lymphoma (all types) and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.